Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue and Organ Procurement | 8 | 2022 | 219 | 3.000 |
Why?
|
| Liver Transplantation | 23 | 2024 | 1038 | 2.820 |
Why?
|
| Tissue Donors | 14 | 2022 | 488 | 2.410 |
Why?
|
| Organ Transplantation | 5 | 2025 | 165 | 2.020 |
Why?
|
| Kidney Transplantation | 7 | 2022 | 638 | 1.430 |
Why?
|
| Donor Selection | 3 | 2020 | 55 | 1.430 |
Why?
|
| Thrombosis | 3 | 2022 | 521 | 1.200 |
Why?
|
| Graft Rejection | 5 | 2025 | 590 | 1.070 |
Why?
|
| Transplant Recipients | 6 | 2025 | 216 | 1.010 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 880 | 0.860 |
Why?
|
| Death | 2 | 2021 | 70 | 0.840 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 182 | 0.820 |
Why?
|
| Waiting Lists | 6 | 2024 | 228 | 0.690 |
Why?
|
| Health Care Rationing | 1 | 2020 | 58 | 0.670 |
Why?
|
| Graft Survival | 10 | 2022 | 532 | 0.650 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 103 | 0.610 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 296 | 0.600 |
Why?
|
| Perioperative Care | 1 | 2020 | 196 | 0.600 |
Why?
|
| Liver Diseases | 1 | 2022 | 366 | 0.590 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 129 | 0.590 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 182 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.530 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 646 | 0.530 |
Why?
|
| Patient Selection | 1 | 2020 | 693 | 0.530 |
Why?
|
| Portal Vein | 3 | 2022 | 92 | 0.520 |
Why?
|
| Pandemics | 2 | 2020 | 1105 | 0.510 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 607 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.470 |
Why?
|
| Registries | 1 | 2019 | 1422 | 0.400 |
Why?
|
| Length of Stay | 5 | 2021 | 1309 | 0.370 |
Why?
|
| Child | 22 | 2025 | 24454 | 0.350 |
Why?
|
| Humans | 41 | 2025 | 124797 | 0.340 |
Why?
|
| Retrospective Studies | 23 | 2025 | 16299 | 0.330 |
Why?
|
| Adolescent | 16 | 2025 | 19329 | 0.310 |
Why?
|
| Allografts | 5 | 2021 | 192 | 0.310 |
Why?
|
| Iliac Vein | 2 | 2019 | 34 | 0.310 |
Why?
|
| Vascular Grafting | 2 | 2019 | 46 | 0.310 |
Why?
|
| Child, Preschool | 15 | 2025 | 14050 | 0.300 |
Why?
|
| Biliary Atresia | 2 | 2023 | 190 | 0.290 |
Why?
|
| Risk Factors | 16 | 2025 | 10272 | 0.270 |
Why?
|
| Treatment Outcome | 12 | 2024 | 12342 | 0.260 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 292 | 0.250 |
Why?
|
| Infant | 13 | 2025 | 12483 | 0.240 |
Why?
|
| Hypernatremia | 1 | 2024 | 29 | 0.230 |
Why?
|
| Male | 22 | 2025 | 61285 | 0.220 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 50 | 0.200 |
Why?
|
| Hepatic Artery | 1 | 2022 | 51 | 0.200 |
Why?
|
| Catheters | 1 | 2022 | 87 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2020 | 334 | 0.190 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 89 | 0.190 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 180 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2903 | 0.180 |
Why?
|
| Age Factors | 6 | 2021 | 2817 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2021 | 103 | 0.180 |
Why?
|
| Hospitalization | 2 | 2020 | 1783 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 462 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 111 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 1028 | 0.170 |
Why?
|
| Public Opinion | 1 | 2020 | 56 | 0.170 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 29 | 0.170 |
Why?
|
| Attitude | 1 | 2020 | 115 | 0.170 |
Why?
|
| Gastroenteritis | 1 | 2023 | 348 | 0.170 |
Why?
|
| Learning Curve | 1 | 2020 | 52 | 0.170 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 67 | 0.160 |
Why?
|
| Models, Anatomic | 1 | 2020 | 99 | 0.160 |
Why?
|
| Renal Veins | 1 | 2019 | 36 | 0.160 |
Why?
|
| Directed Tissue Donation | 1 | 2019 | 2 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2020 | 236 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 68 | 0.160 |
Why?
|
| Female | 20 | 2025 | 66555 | 0.160 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8182 | 0.150 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 168 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 489 | 0.150 |
Why?
|
| Cold Ischemia | 1 | 2018 | 20 | 0.150 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 152 | 0.150 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 40 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 194 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 129 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2022 | 592 | 0.140 |
Why?
|
| Liver Failure | 1 | 2017 | 89 | 0.140 |
Why?
|
| Kidney | 2 | 2022 | 1354 | 0.130 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 27 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 75 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 66 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 638 | 0.130 |
Why?
|
| Aorta | 1 | 2019 | 537 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 862 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 471 | 0.120 |
Why?
|
| Adult | 10 | 2022 | 29472 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 938 | 0.120 |
Why?
|
| Reoperation | 1 | 2018 | 833 | 0.120 |
Why?
|
| Critical Care | 2 | 2017 | 652 | 0.110 |
Why?
|
| United States | 5 | 2020 | 10886 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1319 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 5153 | 0.110 |
Why?
|
| Body Weight | 2 | 2019 | 1005 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1351 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 661 | 0.100 |
Why?
|
| Liver | 4 | 2020 | 1764 | 0.100 |
Why?
|
| Logistic Models | 3 | 2024 | 1810 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3448 | 0.090 |
Why?
|
| Survival Rate | 3 | 2022 | 2035 | 0.090 |
Why?
|
| Pediatrics | 1 | 2019 | 1155 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2024 | 1425 | 0.070 |
Why?
|
| Prognosis | 3 | 2024 | 4607 | 0.070 |
Why?
|
| Middle Aged | 8 | 2020 | 26717 | 0.070 |
Why?
|
| Aged | 7 | 2020 | 19691 | 0.070 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 834 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2018 | 3068 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 64 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 8987 | 0.060 |
Why?
|
| Hyponatremia | 1 | 2024 | 73 | 0.050 |
Why?
|
| Sodium | 1 | 2024 | 295 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2142 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 1109 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 177 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1285 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 85 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 245 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 605 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 3435 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 104 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 6309 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 167 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 227 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1999 | 407 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 778 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 267 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1999 | 356 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 4783 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 472 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 757 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 485 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1247 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1495 | 0.030 |
Why?
|
| Critical Illness | 1 | 2017 | 600 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2880 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1568 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6521 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 1999 | 6 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 65 | 0.010 |
Why?
|
| Temperature | 1 | 1999 | 305 | 0.010 |
Why?
|
| DNA Damage | 1 | 1999 | 515 | 0.010 |
Why?
|
| DNA Repair | 1 | 1999 | 587 | 0.010 |
Why?
|